Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II chemoradiation for unresectable T4 oesophageal cancer
ISRCTN15521056Phase 2Completed
- Sponsor
- Erasmus MC
- Start
- Oct 2003
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and carboplatin in esophageal cancer and esophagogastric junction cancer, sponsored by Erasmus MC. Primary endpoints: Clinically complete biopsy-proven response rate and Toxicity. Started Oct 2003; status: completed.
02
Drugs
paclitaxelcarboplatin
03
Conditions
esophageal canceresophagogastric junction cancer
Beyond the preview
Go deeper on ISRCTN15521056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15521056.